Cancer Chemotherapy Reviews
Thursday, October 22, 2020 
ISSN: 2462-4136
Subscribers area
Home Editorial Board Journal Contents Subscriptions Contact Us Authors Instructions
<<< back |

Transitional Cell Carcinoma of the Ovary: A Case report and Review of the Literature

January-March 2014, Volume 01, Number 1
Jorge Luis Martínez-Tlahuel, Rita Dorantes-Heredia, José Manuel Ruiz-Morales and Jaime G. de la Garza-Salazar
Medical Oncology Department, National Cancer Institute, Mexico City, Mexico

Introduction: Transitional cell carcinoma (TCC) of the ovary resembles urothelial rather than ovarian surface epithelium. The histopathology pattern is diagnostic. Ovary TCC typically shows undulating, diffuse, insular, and trabecular growth patterns. Case presentation: A 72-year-old postmenopausal woman presented with progressive enlargement of abdominal girth and diffuse pain in October 2008. Abdominal ultrasound showed a pelvic mass with homogeneous echogenicity. Routine biologic test results were all within normal ranges; CA-125 below upper limit (35 mUI/l). Surgical staging procedures including total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, and pelvic lymph node dissection were performed. The final diagnosis was TCC of the ovary, grade 3, FIGO stage IIIC. The patient underwent six cycles of chemotherapy with carboplatin and paclitaxel. She was disease-free for 10 months. At progression, liposomal doxorubicin was initiated. At new progression, reintroduction with carboplatin and paclitaxel plus bevacizumab was administered. She had complete response documented by positron emission tomography-computed tomography (PET-CT) scan. Conclusion: Primary TCC of the ovary is a rare subtype of epithelial ovarian cancer. Surgical resection remains the primary therapeutic approach, followed in some cases by adjuvant chemotherapy. It is sensitive to platinum-based combinations. The prognosis of these tumors is better than for other types of ovarian cancers.

Key words:
Transitional cell carcinoma. Epithelial ovarian cancer. Bevacizumab.
[See pdf]
Temístocles, 315 – Colonia Polanco
Delegación Miguel Hidalgo
11560 Ciudad de México
© Permanyer | Made & Powered by PERMANYER | Privacy Policy - Legal notice